Immatics FY2025 EPS Estimate Lifted by Cantor Fitzgerald

Immatics N.V. (NASDAQ:IMTX) – Stock analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Immatics in a research report issued on Wednesday, November 19th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings per share of ($2.09) for the year, up from their previous forecast of ($2.15). The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share. Cantor Fitzgerald also issued estimates for Immatics’ FY2026 earnings at ($1.76) EPS.

Several other brokerages have also recently weighed in on IMTX. Mizuho raised their target price on Immatics from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immatics in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Immatics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 13th. Finally, Guggenheim lifted their price objective on shares of Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $17.33.

Immatics Stock Performance

Shares of IMTX stock opened at $10.20 on Friday. Immatics has a 1 year low of $3.30 and a 1 year high of $11.25. The business’s fifty day moving average is $9.24 and its 200-day moving average is $6.93. The stock has a market cap of $1.24 billion, a PE ratio of -10.00 and a beta of 1.24.

Immatics (NASDAQ:IMTX) last announced its earnings results on Monday, November 17th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.01. The firm had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $12.53 million. Immatics had a negative return on equity of 24.16% and a negative net margin of 146.13%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IMTX. Bank of America Corp DE raised its holdings in shares of Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the period. XTX Topco Ltd purchased a new position in Immatics during the 1st quarter worth approximately $573,000. Russell Investments Group Ltd. acquired a new stake in Immatics during the 1st quarter valued at $430,000. Aberdeen Group plc raised its stake in Immatics by 107.1% during the 1st quarter. Aberdeen Group plc now owns 719,586 shares of the company’s stock valued at $3,245,000 after purchasing an additional 372,207 shares during the period. Finally, Algert Global LLC lifted its holdings in shares of Immatics by 20.6% in the first quarter. Algert Global LLC now owns 70,668 shares of the company’s stock valued at $319,000 after purchasing an additional 12,072 shares in the last quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.